SightfileU.S. market data from official filings

Companies › GKOS

GLAUKOS CORP (GKOS)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001192448 · EDGAR filings · Updated 2026-07-21

GLAUKOS CORP (GKOS) has reported institutional ownership of 98.7%, with 335 institutional managers holding positions valued at $6.25B per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
98.7%
Institutional managers
335
Reported 13F value
$6.25B
Insider activity
118 trans.
−$40.6M net selling
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, GLAUKOS CORP has 335 institutional holders and institutional ownership of 98.7%.

Insider activity

Insiders reported 118 transactions (0 buys, 30 sells) across 11 reporting insiders, with a net reported value of −$40.6M.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2022-02-28 (recurring since 2020-03-02) — source filing. The authoritative details are those stated in the filing itself.

Related companies

RHYTHM PHARMACEUTICALS INC COM (RYTM) · AXSOME THERAPEUTICS INC. (AXSM) · MIRUM PHARMACEUTICALS INC (MIRM) · ALKERMES PLC (ALKS) · CG ONCOLOGY INC (CGON) · CENTESSA PHARMACEUTICALS PLC (CNTA)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-21.